Severe human disease caused by the emerging H7N9 influenza virus in China warrants a rapid response. Here, we present a recombinant Newcastle disease virus expressing a North American lineage H7 influenza virus hemagglutinin. Sera from immunized mice were cross-reactive to a broad range of H7 subtype viruses and inhibited hemagglutination by the novel H7 hemagglutinin. Immunized mice were protected against a heterologous H7 subtype challenge, and genetic analysis suggested that cross-protective antibodies recognize conserved antigenic sites.
N
ovel H7N9 subtype influenza viruses of avian origin have recently emerged in China (1, 2) . H7 subtype viruses have been isolated from humans in several instances and have been recognized as a pandemic threat for the past decade (3) (4) (5) (6) (7) (8) (9) . Clinical symptoms in the vast majority of previously described human H7 influenza cases have been mild; in contrast, many reported human infections with the novel H7N9 influenza virus have been associated with severe disease (1, 2, 4, 6, 7, 9) . Genomic sequence analyses suggest that the novel virus is a triple reassortant of avian strains with the hemagglutinin (HA) derived from a Eurasian H7N3 virus, the neuraminidase from a Eurasian H7N9 or H11N9 virus, and the remaining six segments from a Eurasian H9N2 virus (1, 2) . The possibility of viral transmission from human to human has not been ruled out (10) , and several mutations recognized to support human adaptation have been reported in the novel H7N9 viruses (1, 2) . However, most of the human infections are believed to arise from contact with infected poultry, and H7N9 viruses have also been isolated from chicken and pigeons (2) .
Efforts to restrict avian-to-human transmission are under way in China, as large poultry markets have been shut down throughout the country; however, immunization should play a role in containing the spread of an emerging virus (3, 11, 12) . The development and production of new vaccines can be time-consuming, but significant research toward the development and rapid manufacture of avian and human H7 vaccines is well under way (13) (14) (15) (16) (17) . A large body of research has described cross-reactive antibodies that recognize diverse hemagglutinins (18, 19) , and animal studies have indicated that H7 avian vaccines or infection with wild-type and cold-adapted H7 subtype viruses induces a crossreactive polyclonal response in avian and mammalian species (13, 15, 20) . The ability of existing H7 subtype vaccines in a variety of vectors to induce cross-protective immunity to the novel human isolates of H7N9 influenza virus warrants investigation. Here, we describe the induction of a cross-reactive and broadly protective humoral response by an H7 subtype vaccine candidate in the Newcastle disease virus (NDV) vector, which is well established for use as a bivalent vaccine in poultry against NDV and avian influenza viruses (16, 21) . Recombinant NDV vaccines for avian influenza virus are approved for use and have been widely distributed in China, primarily for H5 subtype but also for H9 subtype influenza viruses, but poultry are not currently immunized against H7 subtype influenza viruses (22, 23) .
The phylogenetic tree presented here highlights the relationship between recent H7N9 isolates, selected H7 subtype HAs that have sporadically caused human disease, and HAs relevant to this study (Fig. 1A) . The Eurasian lineage viruses are genetically distinct from those of the North American lineage; however, further analysis revealed that the putative antigenic sites from HAs of both lineages share conserved sequences (Fig. 1B) . The H7 antigenic sites have been predicted and aligned using a highly structurally similar H3 subtype HA for a reference (24) . These antigenic sites are thought to lie within the immunodominant but hypervariable domains of the HA globular head. Hemagglutination-inhibiting (HAI) neutralizing antibodies are raised against the antigenic sites, but these antibodies are often rendered ineffective after seasonal antigenic drift (25) . Because the putative antigenic sites in H7 subtype HAs appear to be well conserved, we hypothesized that vaccination with a North American lineage HA (A/chicken/ Jalisco/12283/2012), which has also made the zoonotic leap from chickens to humans (4), may induce broadly reactive and crossprotective antibodies against a range of H7 viruses, including the novel H7N9 strains.
Utilizing our reverse genetic system, we rescued a LaSota strain NDV virus carrying the full-length Jalisco HA between the NDV P and M genes to maximize transgene expression ( Fig. 2A) (26) . The Jalisco HA was selected for this study for its high divergence from the novel H7 (Fig. 1A) and for its relevance as the epidemiological agent in recent cases of zoonotic infection from chickens to humans (4). We consider NDV Jalisco a model for studying H7 subtype cross-reactivity that may be induced by this vector system, and we hypothesize that other H7 antigens expressed by NDV may induce humoral responses similar in breadth to what is described here. The polybasic cleavage site present in the wild-type HA was mutated to a low-pathogenicity sequence as indicated ( Fig. 2A ) (primer sequences available upon request). Expression of the H7 transgene was confirmed in A549 cells (ATCC CCL-185) by Western blotting (Fig. 2B ) and in 293T cells (ATCC CRL-11268) by immunofluorescence ( Fig. 2C ) with a polyclonal H7 sera (BEI NR-3152) raised against A/FPV/Dutch/27 (H7N7). Recombinant NDV Jalisco was used to vaccinate mice at two doses, 10 4 focus-forming units (FFU) or 10 6 FFU per animal, administered intranasally in a prime-boost regimen with 4 weeks between immunizations. All mouse experiments were performed under the guidelines of the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (permit LA09-00266). Appropriate care was taken to ensure the animals' welfare and humane endpoints. Animals were bled 4 weeks postboost to confirm seroreactivity to the Jalisco HA antigen (Fig. 3A) and for further serum analysis. Heterologous seroreactivity induced by immunization with NDV Jalisco was first assayed for a near relative, A/mallard/Alberta/24/2001 (Fig. 3B) , and a more distant relative, A/rhea/North Carolina/39482/1993 (Fig. 3C) , in the North American H7 lineage. A more divergent HA, A/mallard/ Netherlands/12/2000, from the Eurasian lineage, was also reactive with sera from NDV Jalisco-immunized mice (Fig. 3D) . Purified HA proteins from novel H7N9 human isolates A/Shanghai/1/ 2013 (Fig. 3E) and A/Anhui/1/2013 (Fig. 3F) were plated at the same concentration as purified HA from A/rhea/North Carolina/ 39482/1993 (Fig. 3G) . Enzyme-linked immunosorbent assays (ELISAs) were performed at the same times, such that these three panels were comparable, and the seroreactivity to each antigen was very similar despite the fact that the novel H7 HAs were much more divergent from the Jalisco immunogen.
In order to crudely map the domain recognized by the crossreactive antisera, a chimeric hemagglutinin (cHA) with the globular head of A/mallard/Alberta/24/2001 recombinantly joined to the stalk of an H3 subtype HA (A/Perth/16/2009) was utilized ( Fig. 3H) (27) . Many broadly reactive antibodies bind to the HA stalk domain across subtypes (18, 28) . We did not, however, detect seroreactivity to full-length H3 subtype HA (Fig. 3I) , indicating that the cross-reactive antibodies induced by NDV Jalisco are directed toward the globular head of the cH7/3 construct (Fig. 3H) . Finally, we found another example to demonstrate that H7 subtype cross-reactivity is a broad phenomenon by staining cells expressing a novel HA from the emerging H7N9 virus in China with serum (BEI NR-9226) raised against a heterologous HA, A/Netherlands/219/03 (H7N7) (Fig. 3J) . Notably, our analysis focused upon the humoral response and broadly reactive antibodies, but we did not exclude the importance of a cross-reactive cellular immune response.
Antibodies to the HA globular head are classically considered to be HAI active and potent neutralizers, but the breadth of their reactivity may be limited due to genetic drift in the antigenic sites (25) . As demonstrated in Fig. 1B , there was a high degree of conservation in the putative antigenic sites across divergent H7 subtype hemagglutinins. In order to test whether the cross-reactive antibodies might be protective, HAI titers were measured. Positive HAI titers against mammalian cell-derived virus-like particles (VLPs) for the Jalisco immunogen were confirmed using pooled serum samples in duplicate (Fig. 4A) (29) . VLPs displaying HA from a newly emergent H7N9 were also assayed. Sera assayed from individual mice immunized with NDV Jalisco also had strong HAI titers against the HA from the novel H7N9 virus in China (Fig.  4B ). An H7N9 "6 ϩ 2" reassortant virus was prepared in the PR8 (A/Puerto Rico/8/34/Mount Sinai) background by using HA and NA from A/Shanghai/1/2013. A positive HAI titer to the H7N9 virus was also confirmed for sera from NDV Jalisco-immunized mice (Fig. 4C) , indicating that antibodies raised against the Jalisco HA are cross-neutralizing to the novel H7N9 virus. Therefore, we present a vaccine ideally vectored (NDV) for avian species that expresses an HA from the North American lineage and induces cross-reactive HAI antibodies to the highly divergent HA of A/Shanghai/1/2013 (H7N9). We hypothesize that these antibodies would be efficacious in vivo via recognition of conserved antigenic sites on the globular head.
To confirm that the immunized animals were protected against a heterologous challenge, we made use of A/rhea/North Carolina/39482/1993 (H7N1). All immunized mice received a challenge of 15 50% mouse lethal doses (mLD 50 ; 5.0 ϫ 10 5 PFU) and were monitored for weight loss for 14 days. Animals falling below the threshold of 80% of their initial body weight were humanely euthanized. The mice immunized with NDV Jalisco at either dose had significantly reduced morbidity as measured by weight loss (Fig. 4D) and improved survival as indicated by Kaplan-Meier curves (Fig. 4E) . Statistics on the survival curves compared animals that received NDV Jalisco to the NDV-green fluorescent protein (GFP) control at equivalent doses and were calculated with the Mantel-Cox test in Prism v6.0b (GraphPad Software).
Here, we have demonstrated that NDV Jalisco raises broadly cross-reactive antibodies to a range of H7 subtype HAs across the North American and Eurasian lineages. Immunized animals were protected against a heterologous challenge virus, and their sera were HAI active to the highly divergent HA of A/Shanghai/1/2013 (H7N9). The data suggest that immunization with H7 subtype 
FIG 3
Immunization of mice with NDV Jalisco induces broadly cross-reactive antibodies to H7 subtype hemagglutinins. Sera from mice primed and boosted at the indicated doses of NDV Jalisco or NDV-GFP were assayed by ELISA for reactivity to a range of H7 subtype hemagglutinins from the North American and Eurasian lineages. Seroreactivity to the immunogen (A) was confirmed and then demonstrated for two North American H7 subtype HAs (B and C) as well as a more distant HA from Europe (D). Reactivities to HAs from novel H7N9 isolates are shown in panels E and F, and seroreactivity to purified HA from A/rhea/North Carolina/39482/93 is presented as a basis for comparison (G). A recombinant, chimeric HA with an H7 subtype globular head and an H3 subtype stalk was utilized to demonstrate reactivity to the H7 head (H), while seroreactivity to an H3N2 virus was not observed (I). Purified HA proteins (A, B, and D to G) (30) or whole-virus preparations (C, H, and I) served as the substrates. Polyclonal sera raised against A/Netherlands/219/03 (H7N7) was reactive to the novel H7 subtype HA from A/Shanghai/1/2013 (H7N9), as shown by immunostaining (J). Sera from immunized animals were pooled and assayed in duplicate (A, B, D, F to I; error bars depict standard deviations), or they were assayed individually (C and E; error bars indicate standard errors of the means).
HAs in NDV can induce broad cross-reactivity that is HAI positive to even distantly related H7 subtype HAs. The basis for this reactivity may lie in the conservation of antigenic sites described here. To conclude, immunization with an avian influenza virus vaccine based upon a North American lineage H7 HA in the NDV LaSota vector raised HAI antibodies to the novel H7N9 influenza virus emerging in China, exemplifying extraordinary cross-reactivity induced by H7 subtype influenza virus hemagglutinins.
